VAX-ID Oncology

Vaccination can have a major impact on the increasing global cancer burden that is expected to exceed 20 million new cases per year in 2025. Where prophylactic vaccination has the potential to prevent cancer caused by HPV or HBV infection, therapeutic vaccination will boost the body's natural defense of people already diagnosed with potentially any type of cancer. Vax-ID, a unique injection system, can be used for both prophylactic and therapeutic intradermal vaccination.

Oncology brochure

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.